Epigenomic charting and functional annotation of risk loci in renal cell carcinomaAmin H. Nassar, Matthew L. Freedman, David A. Braun et al.|Nature Communications|2023Cited by 35
Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell CarcinomaChris Labaki, David A. Braun, Eddy Saad et al.|Journal of Clinical Oncology|2025Cited by 14
831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trialYasmin Nabil Laimon, Sabina Signoretti, Paul Morgan et al.|Laboratory Investigation|2025Cited by 2
Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC).Chris Labaki, David A. Braun, Michel Alchoueiry et al.|Journal of Clinical Oncology|2024Cited by 1
Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.Chris Labaki, Toni K. Choueiri, Long Zhang et al.|Journal of Clinical Oncology|2022Cited by 0